{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"medRxiv"}],"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T08:23:46Z","timestamp":1768551826104,"version":"3.49.0"},"posted":{"date-parts":[[2021,3,24]]},"group-title":"Infectious Diseases (except HIV\/AIDS)","reference-count":25,"publisher":"openRxiv","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2021,6,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                <jats:sec>\n                  <jats:title>BACKGROUND<\/jats:title>\n                  <jats:p>While mRNA vaccines authorized for emergency use are administrated worldwide in an effort to contain the COVID-19 pandemic, little is known about the heterogeneity of the humoral immune response they induce at the population scale.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>METHODS<\/jats:title>\n                  <jats:p>We conducted a prospective observational longitudinal study in 1245 hospital care workers and 146 nursing home residents, together covering adult ages from 19 to 99 years. Blood samples were taken before vaccination, 3-5 weeks after the first vaccine dose, and 3 weeks after the second dose of BNT162b2 mRNA COVID-19 (Comirnaty, Pfizer\/BioNTech). End points were seroconversion to SARS-CoV-2 spike protein and amount of spike-specific IgG, IgM and IgA following the first dose and the boosting effect of the second vaccination. We also addressed the effect of age, sex and pre-exposure to SARSCov-2 on these parameters.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>Among 1067 baseline seronegative participants, seroconversion after the first vaccine dose varied from a maximum of 98,6% in the younger age strata [19-29 years] to a minimum of 25.4 % in the older age group [70-100 years], while sex had little effect. Large inter-individual variation in the amplitude of the antibody response were observed in all age strata. The second dose brought seroconversion to high frequency (100% and 94.9% in younger and older age strata, respectively) and homogenised IgG responses to high levels, while IgM and IgA levels remained low and heterogeneous. Previous exposure to SARS-Cov-2 boosted IgG level after a single injection. Seven non-responders were identified after the second dose.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>In this large study, covering all adult age ranges, BNT162b2 vaccination resulted in isotypic and heterogeneous antibody responses, advocating for the interval between the two doses not to be extended and for serological monitoring of elderly and immunosuppressed vaccinees.<\/jats:p>\n                <\/jats:sec>","DOI":"10.1101\/2021.03.19.21253680","type":"posted-content","created":{"date-parts":[[2021,3,24]],"date-time":"2021-03-24T14:25:19Z","timestamp":1616595919000},"source":"Crossref","is-referenced-by-count":7,"title":["Population homogeneity for the antibody response to COVID-19 BNT162b2 \/ Comirnaty vaccine is only reached after the second dose, across all adult age ranges"],"prefix":"10.64898","author":[{"given":"Jo\u00e3o F.","family":"Viana","sequence":"first","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0691-4308","authenticated-orcid":false,"given":"Marie-Louise","family":"Bergman","sequence":"additional","affiliation":[]},{"given":"L\u00edgia A.","family":"Gon\u00e7alves","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4477-4492","authenticated-orcid":false,"given":"N\u00e1dia","family":"Duarte","sequence":"additional","affiliation":[]},{"given":"Teresa Penha","family":"Coutinho","sequence":"additional","affiliation":[]},{"given":"Patr\u00edcia C.","family":"Borges","sequence":"additional","affiliation":[]},{"given":"Christian","family":"Diwo","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0899-0649","authenticated-orcid":false,"given":"Rute","family":"Castro","sequence":"additional","affiliation":[]},{"given":"Paula","family":"Matoso","sequence":"additional","affiliation":[]},{"given":"Vanessa","family":"Malheiro","sequence":"additional","affiliation":[]},{"given":"Ana","family":"Brennand","sequence":"additional","affiliation":[]},{"given":"Lindsay","family":"Kosack","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5213-4903","authenticated-orcid":false,"given":"Onome","family":"Akpogheneta","sequence":"additional","affiliation":[]},{"given":"Jo\u00e3o M.","family":"Figueira","sequence":"additional","affiliation":[]},{"given":"Concei\u00e7\u00e3o","family":"Cardoso","sequence":"additional","affiliation":[]},{"given":"Ana M.","family":"Casaca","sequence":"additional","affiliation":[]},{"given":"Paula M.","family":"Alves","sequence":"additional","affiliation":[]},{"given":"Telmo","family":"Nunes","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7225-1907","authenticated-orcid":false,"given":"Carlos","family":"Penha-Gon\u00e7alves","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4761-614X","authenticated-orcid":false,"given":"Jocelyne","family":"Demengeot","sequence":"additional","affiliation":[]}],"member":"54368","reference":[{"key":"2021060703501290000_2021.03.19.21253680v2.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2034577"},{"key":"2021060703501290000_2021.03.19.21253680v2.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2027906"},{"key":"2021060703501290000_2021.03.19.21253680v2.3","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2521-4"},{"key":"2021060703501290000_2021.03.19.21253680v2.4","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.smim.2018.10.010","article-title":"Vaccination in the elderly: The challenge of immune changes with aging","volume":"40","year":"2018","journal-title":"Semin Immunol"},{"key":"2021060703501290000_2021.03.19.21253680v2.5","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2016.90"},{"key":"2021060703501290000_2021.03.19.21253680v2.6","doi-asserted-by":"crossref","unstructured":"Wang Z , Schmidt F , Weisblum Y , et al. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. Nature 2021.","DOI":"10.3410\/f.739524179.793585051"},{"key":"2021060703501290000_2021.03.19.21253680v2.7","doi-asserted-by":"crossref","unstructured":"Manisty C , Otter AD , Treibel TA , et al. Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals. Lancet 2021.","DOI":"10.1016\/S0140-6736(21)00501-8"},{"key":"2021060703501290000_2021.03.19.21253680v2.8","unstructured":"Krammer F , Srivastava K , Alshammary H , et al. Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine. N Engl J Med 2021."},{"key":"2021060703501290000_2021.03.19.21253680v2.9","doi-asserted-by":"crossref","unstructured":"Doria-Rose N , Suthar MS , Makowski M , et al. Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19. New England Journal of Medicine 2021.","DOI":"10.1056\/NEJMc2103916"},{"key":"2021060703501290000_2021.03.19.21253680v2.10","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1056\/NEJMoa2028436","article-title":"Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults","volume":"383","year":"2020","journal-title":"New England Journal of Medicine"},{"key":"2021060703501290000_2021.03.19.21253680v2.11","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1001\/jama.2021.3341","article-title":"Binding and Neutralization Antibody Titers After a Single Vaccine Dose in Health Care Workers Previously Infected With SARS-CoV-2","volume":"325","year":"2021","journal-title":"JAMA"},{"key":"2021060703501290000_2021.03.19.21253680v2.12","doi-asserted-by":"crossref","unstructured":"Anichini G , Terrosi C , Gandolfo C , et al. SARS-CoV-2 Antibody Response in Persons with Past Natural Infection. New England Journal of Medicine 2021.","DOI":"10.1056\/NEJMc2103825"},{"key":"2021060703501290000_2021.03.19.21253680v2.13","doi-asserted-by":"crossref","unstructured":"Wise J. Covid-19: People who have had infection might only need one dose of mRNA vaccine. BMJ 2021;372:308.","DOI":"10.1136\/bmj.n308"},{"key":"2021060703501290000_2021.03.19.21253680v2.14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2102017"},{"key":"2021060703501290000_2021.03.19.21253680v2.15","doi-asserted-by":"publisher","DOI":"10.1101\/2020.03.21.990770"},{"key":"2021060703501290000_2021.03.19.21253680v2.16","doi-asserted-by":"publisher","DOI":"10.1172\/JCI140965"},{"key":"2021060703501290000_2021.03.19.21253680v2.17","first-page":"281","article-title":"Persistence of SARS-CoV-2-specific B and T cell responses in convalescent COVID-19 patients 6-8 months after the infection","volume":"2","year":"2021","journal-title":"Med (N Y)"},{"key":"2021060703501290000_2021.03.19.21253680v2.18","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1038\/s41591-020-0913-5","article-title":"A serological assay to detect SARS-CoV-2 seroconversion in humans","volume":"26","year":"2020","journal-title":"Nat Med"},{"key":"2021060703501290000_2021.03.19.21253680v2.19","doi-asserted-by":"crossref","unstructured":"Sterlin D , Mathian A , Miyara M , et al. IgA dominates the early neutralizing antibody response to SARS-CoV-2. Sci Transl Med 2021;13.","DOI":"10.1126\/scitranslmed.abd2223"},{"key":"2021060703501290000_2021.03.19.21253680v2.20","doi-asserted-by":"crossref","unstructured":"Wang Z , Lorenzi JCC , Muecksch F , et al. Enhanced SARS-CoV-2 neutralization by dimeric IgA. Sci Transl Med 2021;13.","DOI":"10.1126\/scitranslmed.abf1555"},{"key":"2021060703501290000_2021.03.19.21253680v2.21","doi-asserted-by":"crossref","unstructured":"Mades A , Chellamathu P , Lopez L , et al. Detection of persistent SARS-CoV-2 IgG antibodies in oral mucosal fluid and upper respiratory tract specimens following COVID-19 mRNA vaccination. medRxiv 2021.2021.05.06.21256403.","DOI":"10.1101\/2021.05.06.21256403"},{"key":"2021060703501290000_2021.03.19.21253680v2.22","doi-asserted-by":"crossref","unstructured":"Ebinger JE , Fert-Bober J , Printsev I , et al. Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2. Nature Medicine 2021.","DOI":"10.1038\/s41591-021-01325-6"},{"key":"2021060703501290000_2021.03.19.21253680v2.23","doi-asserted-by":"crossref","unstructured":"Alenquer M , Ferreira F , Lousa D , et al. Amino acids 484 and 494 of SARS-CoV-2 spike are hotspots of immune evasion affecting antibody but not ACE2 binding. bioRxiv 2021:2021.04.22.441007.","DOI":"10.1101\/2021.04.22.441007"},{"key":"2021060703501290000_2021.03.19.21253680v2.24","doi-asserted-by":"crossref","unstructured":"Monin L , Laing AG , Mu\u00f1oz-Ruiz M , et al. Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study. The Lancet Oncology 2021.","DOI":"10.1016\/S1470-2045(21)00213-8"},{"key":"2021060703501290000_2021.03.19.21253680v2.25","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(21)00947-8","article-title":"Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data","volume":"397","year":"2021","journal-title":"The Lancet"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2021.03.19.21253680","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T14:10:58Z","timestamp":1768486258000},"score":1,"resource":{"primary":{"URL":"http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2021.03.19.21253680"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,24]]},"references-count":25,"URL":"https:\/\/doi.org\/10.1101\/2021.03.19.21253680","relation":{"is-preprint-of":[{"id-type":"doi","id":"10.1038\/s41467-021-27761-z","asserted-by":"subject"}]},"subject":[],"published":{"date-parts":[[2021,3,24]]},"subtype":"preprint"}}